Today, I want to talk to you about a very important development in the stock market, especially related to pharma stocks.
Recently, something happened in the US that has shaken up the entire Indian pharma sector.
On 26 August, US President Donald Trump made a big announcement, he plans to drastically cut drug prices in America.
He even claimed that drug prices may come down by 1,400% to 1,500%.
Now, why should this matter to you or me as investors?
Because the US is the largest buyer of medicines made by Indian pharmaceutical companies.
Let me break this down for you in very simple terms.
Why Is This Important for Indian Pharma Companies?
Most of our Indian pharma companies sell a large portion of their medicines in the US, especially generic medicines.
So if America cuts prices drastically or puts higher import taxes (tariffs) on medicines, companies in India will:
- Earn less money per product
- Face tougher competition from US-based companies
- Have lower profits
- And this can lead to a fall in their stock prices
As a result of these concerns, on 26 August, many pharma stocks in India saw a sharp fall.
Now, let’s look at three major Indian pharma companies that are being affected the most — and what it means for you as an investor.
Zydus Lifesciences – Big Presence, Big Risk
Zydus is one of India’s top pharma companies.
It makes medicines in areas like:
- Heart and diabetes
- Cancer
- Kidney and liver diseases
- Women’s health
- Respiratory problems
But what makes Zydus stand out is its huge exposure to the US market.
In FY25, almost 49% of its total income came from the US alone.
That’s nearly half the business.
Here’s what you should know:
- Zydus has over 225 generic products in the US
- It is among the top 5 generic drugmakers in the US by prescription volume
- In fact, in nearly 25% of its product categories, Zydus is the market leader
This strong presence sounds good — but it also means Zydus is very sensitive to what happens in the US market.
If prices fall or the US puts extra taxes on imported drugs, Zydus’s profits could get squeezed.
However, the company is also diversifying into new areas like liquid oral medicines (for children and elderly people), which may help in the long run.
Sun Pharma – A Balanced but Cautious Outlook
Sun Pharma is India’s largest pharmaceutical company.
It’s a strong brand, known for both prescription and over-the-counter (OTC) products like Volini and Revital.
Key points about Sun Pharma:
- It has 28 brands among the top 300 in India
- It sells in more than 100 countries
- It makes both raw materials (APIs) and finished medicines
Now coming to the US business:
- The US brings in around 31% of Sun Pharma’s total revenues
- In FY25, Sun earned about Rs 162 billion from the US
Unlike Zydus, Sun’s US business is not just about generics.
It has a growing speciality segment, which is less affected by pricing cuts.
That’s a plus.
But there are some concerns too:
- Its generic business in the US is under pressure
- There’s high competition and some manufacturing issues
- If price cuts continue, profits could get affected
Sun Pharma expects its overall income to grow by mid to high single digits in FY26.
It is also investing more in research, especially for new speciality medicines.
So, while there are risks, Sun’s diverse portfolio provides some balance.
Dr Reddy’s Laboratories – Solid Growth but Sensitive to Pricing
Dr Reddy’s is another big name in the pharma world.
It sells:
- Generic medicines
- Branded generics
- APIs (raw material for drugs)
- Biosimilars
- OTC products
It works across many disease areas like cancer, diabetes, skin, stomach, and pain.
Now let’s look at its US presence.
- In FY25, the US (or North America) contributed about 45% of Dr Reddy’s total revenue
- It earned nearly Rs 145.2 billion from this region, with 12% YoY growth
The growth came from:
- Higher volumes in base products (like Lenalidomide)
- Expanding product portfolio
But the worry is — pricing pressure.
In the US, large buyers often negotiate very low prices, especially for generic drugs.
If US prices fall further, Dr Reddy’s may see margin pressure, even if it sells more volume.
This is something to keep in mind if you’re investing for the long term.
A Look at the Bigger Picture – Pharma Still Has Growth Potential
While the current news seems negative, here’s the good news:
- US pharma spending is expected to grow by US$ 299 billion by 2028
- Around 250+ new medicines are expected to be launched
- There will be major innovations in areas like:
- Cancer
- Diabetes
- Obesity
- Immunology
This means Indian companies that continue to innovate, diversify their portfolios, and build speciality products can still benefit in the long run.
Final Thoughts – What Should You Do Now?
Here’s my simple advice:
- Don’t panic because of short-term price movements
- Keep an eye on companies with strong management and global presence
- Look for pharma companies that are not entirely dependent on the US
- Diversify your portfolio to reduce risk
- If unsure, talk to a trusted advisor before making decisions
Pharma is a defensive sector — it does well even when the overall economy slows down.
Yes, there will be ups and downs, especially when global policy changes.
But companies that keep investing in innovation, quality, and global reach will continue to deliver in the long term.
Stay informed. Stay invested. And always invest wisely.
